JP7175914B2 - 血漿カリクレイン阻害剤としてのヘテロアリールカルボキサミド誘導体 - Google Patents

血漿カリクレイン阻害剤としてのヘテロアリールカルボキサミド誘導体 Download PDF

Info

Publication number
JP7175914B2
JP7175914B2 JP2019556654A JP2019556654A JP7175914B2 JP 7175914 B2 JP7175914 B2 JP 7175914B2 JP 2019556654 A JP2019556654 A JP 2019556654A JP 2019556654 A JP2019556654 A JP 2019556654A JP 7175914 B2 JP7175914 B2 JP 7175914B2
Authority
JP
Japan
Prior art keywords
methyl
group
compound
mixture
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517619A (ja
JP2020517619A5 (enExample
Inventor
サラ フラッティーニ
イアン リンガード
ディーター ヴォルフガング ハンプレヒト
レムコ アレクサンダー バッカー
マティアス エックハルト
アンドレアス ゴルナー
イェルク ピー ヘーン
エルケ ラングコップ
ホルガー ワグナー
ベルント ヴェレンツォーン
ディーター ヴィーデンマイヤー
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2020517619A publication Critical patent/JP2020517619A/ja
Publication of JP2020517619A5 publication Critical patent/JP2020517619A5/ja
Application granted granted Critical
Publication of JP7175914B2 publication Critical patent/JP7175914B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2019556654A 2017-04-21 2018-04-16 血漿カリクレイン阻害剤としてのヘテロアリールカルボキサミド誘導体 Active JP7175914B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17167549.9 2017-04-21
EP17167549 2017-04-21
PCT/EP2018/059633 WO2018192866A1 (en) 2017-04-21 2018-04-16 Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors

Publications (3)

Publication Number Publication Date
JP2020517619A JP2020517619A (ja) 2020-06-18
JP2020517619A5 JP2020517619A5 (enExample) 2021-05-27
JP7175914B2 true JP7175914B2 (ja) 2022-11-21

Family

ID=58606127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556654A Active JP7175914B2 (ja) 2017-04-21 2018-04-16 血漿カリクレイン阻害剤としてのヘテロアリールカルボキサミド誘導体

Country Status (7)

Country Link
US (1) US10501440B2 (enExample)
EP (1) EP3612523B1 (enExample)
JP (1) JP7175914B2 (enExample)
CN (1) CN110546146B (enExample)
AR (1) AR111414A1 (enExample)
TW (1) TW201902887A (enExample)
WO (1) WO2018192866A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839711A (zh) 2018-10-10 2021-05-25 勃林格殷格翰国际有限公司 作为血浆激肽释放酶抑制剂的苯基四唑衍生物
TW202144331A (zh) * 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
TW202535863A (zh) * 2020-02-13 2025-09-16 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
EP4178620A4 (en) * 2020-07-10 2024-08-07 Merck Sharp & Dohme LLC PLASMA KALLICREIN INHIBITORS
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013111108A1 (en) 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
JP2016519156A (ja) 2013-05-23 2016-06-30 カルビスタ・ファーマシューティカルズ・リミテッド 複素環式誘導体
JP2018535963A (ja) 2015-10-27 2018-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687795B (zh) 2011-07-21 2016-05-11 蒂森克虏伯系统工程股份有限公司 用于在传送装置上停止和/或对准运输货物的器件和方法以及传送装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013111108A1 (en) 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
JP2016519156A (ja) 2013-05-23 2016-06-30 カルビスタ・ファーマシューティカルズ・リミテッド 複素環式誘導体
JP2018535963A (ja) 2015-10-27 2018-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体

Also Published As

Publication number Publication date
EP3612523A1 (en) 2020-02-26
JP2020517619A (ja) 2020-06-18
AR111414A1 (es) 2019-07-10
CN110546146B (zh) 2023-02-21
WO2018192866A1 (en) 2018-10-25
US10501440B2 (en) 2019-12-10
US20180305339A1 (en) 2018-10-25
CN110546146A (zh) 2019-12-06
EP3612523B1 (en) 2021-06-09
TW201902887A (zh) 2019-01-16

Similar Documents

Publication Publication Date Title
JP7175914B2 (ja) 血漿カリクレイン阻害剤としてのヘテロアリールカルボキサミド誘導体
EP3368524B1 (en) Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
EP3368529A1 (en) Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
CN113039181B (zh) 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物
JP7703587B2 (ja) 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体
US11851418B2 (en) Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors
JP7378470B2 (ja) 血漿カリクレイン阻害剤としてのフェニルテトラゾール誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220706

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221109

R150 Certificate of patent or registration of utility model

Ref document number: 7175914

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250